Epidemiology of Fabry disease in patients in hemodialysis in the Madrid community.

Unlabelled: This study screened for Fabry disease (FD) in patients in hemodialysis (HD) in the region of Madrid (CAM) with a cross-sectional design to evaluate HD-prevalent patients, followed by a three-year period prospective design to analyze HD-incident patients.

Inclusion Criteria: patients older than 18 years on HD in the CAM, excluding patients diagnosed with any other hereditary disease with renal involvement different from FD, that sign the Informed Consent (IC).

Exclusion Criteria: underaged patients or not agreeing or not being capable of signing the IC.

Sacubitril/valsartan in chronic kidney disease, the nephrologist point of view.

Background And Objectives: Sacubitril/valsartan reduces cardiovascular morbidity and mortality in patients with systolic dysfunction. The aim of the present study was to assess the evolution of chronic kidney disease (CKD) patients after initiating sacubitril/valsartan.

Material And Methods: We included 66 consecutive CKD patients with systolic dysfunction followed up in outpatient care.